Capricor Therapeutics
CAPR
25 hedge funds and large institutions have $5.14M invested in Capricor Therapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0.92% more ownership
Funds ownership: 6.41% → 7.33% (+0.92%)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
6% less call options, than puts
Call options by funds: $851K | Put options by funds: $910K
23% less capital invested
Capital invested by funds: $6.64M → $5.14M (-$1.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$804K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$343K |
| 3 |
Millennium Management
New York
|
+$214K |
| 4 |
Bank of New York Mellon
New York
|
+$125K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$68.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$444K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$85K |
| 3 |
Jane Street
New York
|
-$68K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$63.1K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$45.3K |
CAPR Hedge Fund Activity: Q4 2020 in Review
25 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2020, worth a combined $5.14M — down 23% from $6.64M a quarter earlier.
Fund positioning in CAPR was balanced in Q4 2020: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $804K. The largest seller was Susquehanna International Group, cutting an estimated $444K.
- 25 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $5.14M of Capricor Therapeutics stock for Q4 2020, down 23% quarter-over-quarter.
- 5 funds opened new Capricor Therapeutics positions in Q4 2020 and 5 closed out, a net change of 0 holders.
- The largest Capricor Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $804K added.
- The largest Capricor Therapeutics seller in Q4 2020 was Susquehanna International Group, an estimated $444K sold.
Based on aggregated 13F filings for Q4 2020.